Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ThisCART22 cells
- Development stage
- Phase 1
- Lead developer
- Fundamenta Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ThisCART22 cells is an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed by Fundamenta Therapeutics. It is designed to target the CD22 antigen, a transmembrane glycoprotein expressed on the surface of mature B cells and most B-cell malignancies. Unlike traditional autologous CAR-T therapies that use a patient's own cells, ThisCART22 is derived from healthy donors using a proprietary non-gene-editing approach. The therapy is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed and/or refractory CD22-positive B-cell malignancies, including non-Hodgkin's B-cell lymphoma (r/r B-NHL).
- Other names
- Allogeneic CAR-T targeting CD22
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on ThisCART22 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ThisCART22 cells.